对标K药,三生制药赢麻了

生物制品圈
31 May

2025年5月,三生制药以一场震撼行业的“王炸级”操作赢麻了,60.5亿美元天价BD交易刷新国产创新药出海天花板,其PD-1/VEGF双抗SSGJ-707凭借“Best-in-Class”临床数据成为“下一个K药”有力竞争者。01天价BD,孕育下一个K药2025年5月20日,中国生物医药行业迎来历史性时刻——三生制药宣布与辉瑞达成总额60.5亿美元的授权协议,将其PD-1/VEGF双抗SSGJ-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10